Similar articles

• Hypoxia-selective antitumor agents. 10. bis(nitroimidazoles) and related Bis(nitroheterocycles): development of derivatives with higher rates of metabolic activation under hypoxia and improved aqueous solubility.

  Hay MP, Lee HH, Wilson WR, Roberts PB, Denny WA. Hay MP, et al. J Med Chem. 1995 May 26;38(11):1928-41. doi: 10.1021/jm00011a013. J Med Chem. 1995. PMID: 7783125
• Synthesis of novel 2-nitroimidazole-tethered tricyclic quinolines, bearing a second heteroatom, and their in vitro evaluation as hypoxia-selective cytotoxins and radiosensitizers.

  Papadopoulou MV, Rosenzweig HS, Bloomer WD. Papadopoulou MV, et al. Bioorg Med Chem Lett. 2004 Mar 22;14(6):1523-5. doi: 10.1016/j.bmcl.2003.12.102. Bioorg Med Chem Lett. 2004. PMID: 15006395
• Potential radiosensitizing agents. 7. 4(5)-Iodo-5(4)-nitroimidazole derivatives.

  Gupta RP, Larroquette CA, Agrawal KC, Grodkowski J, Neta P. Gupta RP, et al. J Med Chem. 1985 Aug;28(8):987-91. doi: 10.1021/jm00146a003. J Med Chem. 1985. PMID: 4020837
• The use of nitroaromatic compounds as hypoxic cell radiosensitizers.

  Wardman P. Wardman P. Curr Top Radiat Res Q. 1977 Aug;11(4):347-98. Curr Top Radiat Res Q. 1977. PMID: 330116 Review. No abstract available.
• Nitroimidazole radiosensitizers: approaches to their chemical synthesis.

  Monney H, Parrick J, Wallace RG. Monney H, et al. Pharmacol Ther. 1981;14(2):197-216. doi: 10.1016/0163-7258(81)90061-9. Pharmacol Ther. 1981. PMID: 7031707 Review. No abstract available.